Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release
Read More 6 minute read Pharma Industry News FDA doubles down on Palvella’s QTORIN rapamycin as Phase 3 SELVA trial exceeds enrollment Find out how the FDA’s renewed orphan grant is accelerating Palvella Therapeutics’ Phase 3 QTORIN trial toward potential approval in rare disease care. bySoujanya RaviOctober 13, 2025